The NIH funding provides non-dilutive capital to advance Clene's CNM-Au8 program in ALS, reducing near-term financing risk. Traders should monitor clinical updates from the expanded access program, as positive outcomes could support future regulatory approval and commercialization prospects.
Price Chart
Executive Summary
Clene Inc. entered into a $8.04 million subaward agreement with New York University (NYU) for the third year of a National Institutes of Health (NIH) grant to fund an expanded access program for its CNM-Au8 treatment in amyotrophic lateral sclerosis (ALS). The agreement covers the period from September 1, 2025, to August 31, 2026, and is reimbursable based on submitted costs.
Key Financial Metrics
Key Facts
- Clene Nanomedicine, Inc. (subsidiary of Clene Inc.) entered into a subaward agreement with NYU on March 13, 2026.
- The subaward is for up to $8.04 million (exactly $8,043,660.83) for the third year of a four-year NIH grant.
- Funds will be disbursed based on cost reimbursement for allowable expenses incurred in the expanded access program for CNM-Au8 in ALS patients.
- The subaward period runs from September 1, 2025, to August 31, 2026.
- Either party may terminate the agreement with 30 days' written notice.
- Clene retains full rights to its background intellectual property developed prior to the agreement.
Financial Impact
$8.04 million in reimbursable funding over one year
Risk Factors
- Funding is cost-reimbursable and contingent on Clene incurring eligible expenses.
- The program's success depends on clinical outcomes, which are uncertain.
- Termination by either party with 30 days' notice introduces execution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-008482 |
| Document: clnn20260316_8k.htm | 0001437749-26-008482 |
| Document: 0001437749-26-008482-index-headers.html | 0001437749-26-008482 |
| Document: 0001437749-26-008482-index.html | 0001437749-26-008482 |
| Document: 0001437749-26-008482.txt | 0001437749-26-008482 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $3.73 | awaiting T+20 | — | $3.95 (+5.90%) |
Oct 19, 2026 8d ago | 8-K | $3.29 | awaiting T+20 | — | $3.95 (+20.06%) |
Oct 19, 2026 8d ago | Press Release | $3.29 | awaiting T+20 | — | $3.95 (+20.06%) |
Oct 13, 2026 14d ago | SC 13G/A | $3.39 | awaiting T+20 | — | $3.95 (+16.52%) |
Sep 16, 2026 5w ago | 8-K | $4.15 $3.31 | ▲ +20.36% | ▲ +21.57% | $3.95 (+4.82%) |
Sep 16, 2026 5w ago | 424B5 | $3.86 $3.31 | ▲ +14.25% | ▲ +16.31% | $3.95 (−2.33%) |
Aug 14, 2026 10w ago | 8-K | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.95 (−4.59%) |
Aug 14, 2026 10w ago | Press Release | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.95 (−4.59%) |
Aug 10, 2026 11w ago | 8-K | $5.16 $3.62 | ▼ −29.84% | ▼ −28.93% | $3.95 (−23.45%) |
May 14, 2026 23w ago | 8-K | $7.05 $5.84 | ▼ −17.16% | ▼ −16.30% | $3.95 (−43.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers